N-Acetylcysteine lysinate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530773

CAS#: 89344-48-9

Description: N-Acetylcysteine lysinate is a bioactive chemical.

Chemical Structure

img
N-Acetylcysteine lysinate
CAS# 89344-48-9
Instruction

Theoretical Analysis

MedKoo Cat#: 530773
Name: N-Acetylcysteine lysinate
CAS#: 89344-48-9
Chemical Formula: C11H23N3O5S
Exact Mass: 309.14
Molecular Weight: 309.381
Elemental Analysis: C, 42.70; H, 7.49; N, 13.58; O, 25.86; S, 10.36

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 616-91-1 (Ac-cysteine)   56-87-1 (lysine)   89344-48-9    

Synonym: N-Acetylcysteine lysinate

IUPAC/Chemical Name: L-Cysteine, N-acetyl-, compd. with L-lysine

InChi Key: YLCSLYZPLGQZJS-VDQHJUMDSA-N

InChi Code: InChI=1S/C6H14N2O2.C5H9NO3S/c7-4-2-1-3-5(8)6(9)10;1-3(7)6-4(2-10)5(8)9/h5H,1-4,7-8H2,(H,9,10);4,10H,2H2,1H3,(H,6,7)(H,8,9)/t5-;4-/m00/s1

SMILES Code: SC[C@@H](C(O)=O)NC(C)=O.N[C@@H](CCCCN)C(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 309.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Debelec-Butuner B, Alapinar C, Varisli L, Erbaykent-Tepedelen B, Hamid SM, Gonen-Korkmaz C, Korkmaz KS. Inflammation-mediated abrogation of androgen signaling: an in vitro model of prostate cell inflammation. Mol Carcinog. 2014 Feb;53(2):85-97. doi: 10.1002/mc.21948. Epub 2012 Aug 21. PubMed PMID: 22911881.

2: Haxaire C, Turpin FR, Potier B, Kervern M, Sinet PM, Barbanel G, Mothet JP, Dutar P, Billard JM. Reversal of age-related oxidative stress prevents hippocampal synaptic plasticity deficits by protecting D-serine-dependent NMDA receptor activation. Aging Cell. 2012 Apr;11(2):336-44. doi: 10.1111/j.1474-9726.2012.00792.x. Epub 2012 Feb 1. PubMed PMID: 22230264.

3: Yang W, Hu B, Chen G, Bielefeld EC, Henderson D. [L-NAC protect hair cells in the rat cochlea from injury of exposure to styrene]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011 Feb;25(4):176-9. Chinese. PubMed PMID: 21563467.

4: Maniu A, Perde-Schrepler M, Cosgarea M. Protective effect of L-N-acetylcysteine against gentamycin ototoxicity in the organ cultures of the rat cochlea. Rom J Morphol Embryol. 2011;52(1):159-64. PubMed PMID: 21424048.

5: Stockwin LH, Han B, Yu SX, Hollingshead MG, ElSohly MA, Gul W, Slade D, Galal AM, Newton DL, Bumke MA. Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction. Int J Cancer. 2009 Sep 15;125(6):1266-75. doi: 10.1002/ijc.24496. Erratum in: Int J Cancer. 2010 Dec;127(11):E1. Bumke, Maja A [added]. PubMed PMID: 19533749; PubMed Central PMCID: PMC2752979.

6: Vosters O, Beuneu C, Goldman M, Verhasselt V. N-acetylcysteine derivative inhibits CD40-dependent proinflammatory properties of human pancreatic duct cells. Pancreas. 2008 May;36(4):363-8. doi: 10.1097/MPA.0b013e31815c75d4. PubMed PMID: 18437082.

7: Alipour M, Omri A, Smith MG, Suntres ZE. Prophylactic effect of liposomal N-acetylcysteine against LPS-induced liver injuries. J Endotoxin Res. 2007;13(5):297-304. PubMed PMID: 17986488.

8: Kushwah R, Oliver JR, Cao H, Hu J. Nacystelyn enhances adenoviral vector-mediated gene delivery to mouse airways. Gene Ther. 2007 Aug;14(16):1243-8. Epub 2007 May 24. PubMed PMID: 17525704.

9: Van Antwerpen P, Boudjeltia KZ, Babar S, Legssyer I, Moreau P, Moguilevsky N, Vanhaeverbeek M, Ducobu J, Nève J. Thiol-containing molecules interact with the myeloperoxidase/H2O2/chloride system to inhibit LDL oxidation. Biochem Biophys Res Commun. 2005 Nov 11;337(1):82-8. PubMed PMID: 16171780.

10: Kishida KT, Pao M, Holland SM, Klann E. NADPH oxidase is required for NMDA receptor-dependent activation of ERK in hippocampal area CA1. J Neurochem. 2005 Jul;94(2):299-306. PubMed PMID: 15998281; PubMed Central PMCID: PMC3544193.

11: Antonicelli F, Brown D, Parmentier M, Drost EM, Hirani N, Rahman I, Donaldson K, MacNee W. Regulation of LPS-mediated inflammation in vivo and in vitro by the thiol antioxidant Nacystelyn. Am J Physiol Lung Cell Mol Physiol. 2004 Jun;286(6):L1319-27. PubMed PMID: 15136298.

12: Poser I, Rahman Q, Lohani M, Yadav S, Becker HH, Weiss DG, Schiffmann D, Dopp E. Modulation of genotoxic effects in asbestos-exposed primary human mesothelial cells by radical scavengers, metal chelators and a glutathione precursor. Mutat Res. 2004 Apr 11;559(1-2):19-27. PubMed PMID: 15066570.

13: Brown DM, Donaldson K, Borm PJ, Schins RP, Dehnhardt M, Gilmour P, Jimenez LA, Stone V. Calcium and ROS-mediated activation of transcription factors and TNF-alpha cytokine gene expression in macrophages exposed to ultrafine particles. Am J Physiol Lung Cell Mol Physiol. 2004 Feb;286(2):L344-53. Epub 2003 Oct 10. PubMed PMID: 14555462.

14: Vosters O, Nève J, De Wit D, Willems F, Goldman M, Verhasselt V. Dendritic cells exposed to nacystelyn are refractory to maturation and promote the emergence of alloreactive regulatory t cells. Transplantation. 2003 Feb 15;75(3):383-9. PubMed PMID: 12589163.

15: Sun F, Tai S, Lim T, Baumann U, King M. Additive effect of dornase alfa and Nacystelyn on transportability and viscoelasticity of cystic fibrosis sputum. Can Respir J. 2002 Nov-Dec;9(6):401-6. PubMed PMID: 12522485.

16: Antonicelli F, Parmentier M, Drost EM, Hirani N, Rahman I, Donaldson K, MacNee W. Nacystelyn inhibits oxidant-mediated interleukin-8 expression and NF-kappaB nuclear binding in alveolar epithelial cells. Free Radic Biol Med. 2002 Mar 15;32(6):492-502. PubMed PMID: 11958950.

17: App EM, Baran D, Dab I, Malfroot A, Coffiner M, Vanderbist F, King M. Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis. Eur Respir J. 2002 Feb;19(2):294-302. PubMed PMID: 11866009.

18: Ferrari S, Kitson C, Farley R, Steel R, Marriott C, Parkins DA, Scarpa M, Wainwright B, Evans MJ, Colledge WH, Geddes DM, Alton EW. Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium. Gene Ther. 2001 Sep;8(18):1380-6. PubMed PMID: 11571577.

19: Vanderbist F, Wery B, Baran D, Van Gansbeke B, Schoutens A, Moës AJ. Deposition of nacystelyn from a dry powder inhaler in healthy volunteers and cystic fibrosis patients. Drug Dev Ind Pharm. 2001;27(3):205-12. PubMed PMID: 11291200.

20: Vanderbist F, Wery B, Moyano-Pavon I, Moës AJ. Optimization of a dry powder inhaler formulation of nacystelyn, a new mucoactive agent. J Pharm Pharmacol. 1999 Nov;51(11):1229-34. PubMed PMID: 10632079.